The CMS approval is a critical regulatory milestone that not only validates the potential of BioCardia's CardiAMP Cell Therapy but also likely accelerates its development by facilitating patient enrollment in the Phase III study. This development is expected to positively impact BioCardia's stock in the short term as it enhances investor confidence in the company's pipeline and its ability to bring innovative treatments to market.